LENZ Therapeutics Q3 net loss $10.2M, cash $217.2M; LNZ100 NDA accepted, PDUFA Aug 8, 2025

LENZ Therapeutics, Inc.

2024-Q3 EPS reported -$1.93

Net loss $10.2M ($0.38/share) for Q3 2024 vs $18.9M ($9.62/share) in Q3 2023.
Cash, equivalents and marketable securities $217.2M as of Sept 30, 2024; cash runway to post-launch positive operating cash flow.
FDA accepted NDA for LNZ100 (aceclidine) for presbyopia; PDUFA target action date Aug 8, 2025.
Positive topline Phase 3 data from China: 74% of patients achieved 3-line or greater improvement at 3 hours (p<0.0001).
Completed $30M private placement with Ridgeback Capital in July 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.